a Department of Parasitology, Faculty of Medicine , University of Colombo , Sri Lanka.
b Department of Clinical Medicine, Faculty of Medicine , University of Colombo , Sri Lanka.
Pathog Glob Health. 2017 Sep;111(6):317-326. doi: 10.1080/20477724.2017.1361564. Epub 2017 Aug 18.
Sri Lanka is a new focus of human cutaneous leishmaniasis caused by a genetic variant of usually visceralizing parasite Leishmania donovani. Over 3000 cases have been reported to our institution alone, during the past two decades. Recent emergence of visceral leishmaniasis is of concern.
Patients suspected of having visceral leishmaniasis (n = 120) fulfilling at least two of six criteria (fever > 2 weeks, weight loss, tiredness affecting daily functions, splenomegaly, hepatomegaly and anemia) were studied using clinic-epidemiological, immunological and haematological parameters. Seven cases (four progressive, treated (group A) and 3 non- progressive, potentially asymptomatic and observed (group B) were identified. Clinical cases were treated with systemic sodium stibogluconate or amphotericin B and all were followed up at the leishmaniasis clinic of University of Colombo for 3 years with one case followed up for 9 years.
All treated cases responded well to anti leishmanial treatment. Relapses were not noticed. Clinical features subsided in all non-progressive cases and did not develop suggestive clinical features or change of laboratory parameters. Visceral leishmaniasis cases have been originated from different districts within the country. Majority had a travel history to identified local foci of cutaneous leishmaniasis.
Visceral leishmaniasis is recognized as an emerging health threat in Sri Lanka. At least a proportion of locally identified strains of L. donovani possess the ability to visceralize. Apparent anti leishmanial sensitivity is encouraging. Timely efforts in disease containment will be important in which accurate understanding of transmission characteristics, increased professional and community awareness, improved diagnostics and availability of appropriate treatment regimens.
斯里兰卡是一种新型的人类皮肤利什曼病疫区,其由利什曼原虫的遗传变异引起,这种寄生虫通常会导致内脏利什曼病。仅在过去二十年中,我们机构就报告了超过 3000 例病例。最近内脏利什曼病的出现令人担忧。
对至少满足六个标准中的两个(发热超过 2 周、体重减轻、影响日常功能的疲劳、脾肿大、肝肿大和贫血)的疑似内脏利什曼病患者(n=120)进行了临床流行病学、免疫和血液学参数研究。确定了 7 例(4 例进展性、治疗(A 组)和 3 例非进展性、潜在无症状和观察(B 组))。临床病例采用全身葡甲胺锑酸钠或两性霉素 B 治疗,所有病例均在科伦坡大学利什曼病诊所随访 3 年,其中 1 例随访 9 年。
所有治疗病例均对抗利什曼病治疗反应良好。未发现复发。所有非进展性病例的临床症状均消退,且未出现提示性临床症状或实验室参数变化。内脏利什曼病病例来自该国不同地区。大多数患者有前往已识别的皮肤利什曼病当地疫区的旅行史。
内脏利什曼病在斯里兰卡被认为是一种新出现的健康威胁。至少有一部分本地鉴定的利什曼原虫菌株具有内脏化的能力。明显的抗利什曼敏感性令人鼓舞。及时进行疾病控制将非常重要,其中包括准确了解传播特征、提高专业和社区意识、改进诊断和提供适当的治疗方案。